Health Care & Hospital Law
Jan. 4, 2011
Drug Delays Deals Are Lucrative and Rising
With few wins to date, the Federal Trade Commission hasn't given up on its mission to end patent settlements between pharmaceutical companies and generic drug manufacturers.
By Mandy Jackson
Daily Journal Staff Writer
Despite little success, the Federal Trade Commission hasn't given up on its mission to end patent settlements between pharmaceutical companies and generic drug manufacturers.
The FTC claims "pay-for-delay" agreements in which patent holders pay competitors to postpone the launch of generic versions of brand-name medications violate antitrust law by limiting competition, costing consumer...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In